

The Nightingale Health Check – Longitude

The first commercially-available NMR metabolomic screening platform for cardiometabolic disease, at population scale.

What it is

A single blood test – venous or finger-prick – that uses Nuclear Magnetic Resonance spectroscopy to measure approximately 250 circulating biomarkers, then applies machine-learning models trained on more than one million participants across 14 international biobanks to generate validated 10-year risk-stratification scores across five domains, delivered as green / amber / red categorisation against age- and sex-matched peers for immediate clinical use.

Cardiovascular <i>MI · Stroke</i>	Type 2 diabetes	Chronic kidney disease	Fatty liver disease <i>MASLD</i>	Metabolic age <i>vs chronological</i>
---	----------------------------	-----------------------------------	--	---

What makes it distinctive

- For chronic kidney disease and fatty liver disease in patients with currently normal function, no other validated population-level predictive tool exists. The NHC provides both from the same sample.
- Metabolomic profiles respond to intervention – the platform functions as both a screening tool and an intervention-monitoring instrument as patients change diet, activity, medication, or clinical programme.
- Composite AI-derived output – clinicians receive an actionable risk assessment, not a data dump.

EVIDENCE

Foundational validation: Nightingale Health Biobank Collaborative Group (Nature Communications, 2024) — 700,217 participants across UK, Estonian, and Finnish THL biobanks. Over 900 peer-reviewed publications across Nature Medicine, Circulation, The Lancet, BMJ and others.

REGULATORY

CE-marked under EU MDR (Class I; Class IIa upclassification in progress). CE-IVDR blood-collection kit. UKCA-marked for the UK. New York State CLEP-registered for the US.

DEPLOYED

Finland — national scale in primary care through Terveystalo (~30% of Finnish workforce). US — Weill Cornell Medicine, Boston Heart Diagnostics, Mass General Brigham Biobank. Not experimental.

In Jersey

Archipelago Health is the Channel Islands distributor. Local product identity: **Longitude**. Clinical governance under Dr Jeff MacLeod FRCGP, (Founder), and Prof Andrew Krentz (Chief Clinical Advisor, King's College London). Public unveil at Jersey's TEKEX innovation event on 24 September 2026; first commercial deployment mid-November through partner GP practices, private laboratories, and corporate wellness programmes.

Happy to send the full Clinical Science & Evidence Guide or discuss in a call – just say the word.

Dr Jeffrey MacLeod FRCGP · Founder, Archipelago Health · enquiries@archipelagohealth.org